Aptar Pharma Expands Congers Facility to Meet Growing North American Demand

Key Highlights:

  • 28,500 sq. ft. manufacturing expansion at Congers, NY facility to meet rising demand.

  • Supports proprietary drug delivery systems, including Unidose® Nasal Spray Systems.

  • Expansion aligns with Aptar’s global growth strategy for North America.

  • New cleanroom capabilities and expanded manufacturing footprint.

  • Dedicated production for ETFE PremiumCoat® stoppers for the injectables market.

Notable Quotes:

“This is a key step in the next phase of our global expansion program… Expanding our capacity in Congers, New York is in line with Aptar’s ‘local for local’ strategy to meet the growing needs of our Pharma customers in North America.”

Stephan Tanda, President and CEO at Aptar

“We are proud to be the go-to drug delivery expert who transforms ideas into market opportunities, and accelerates and de-risks the product development process.”

Gael Touya, President at Aptar Pharma

Our Take:

Aptar Pharma’s continued investment in its Congers facility marks a significant move in its strategy to meet the increasing demand for drug delivery solutions in North America. This expansion not only strengthens its position in the nasal and injectable drug delivery markets but also enhances its ability to innovate in critical areas like patient care and sustainability. As healthcare needs grow, Aptar’s strategic focus on localized production ensures it can continue to deliver reliable, cutting-edge solutions while remaining responsive to the regional market demands.